Table 3 Comparison of the clinical factors between patients with and without AE-ILD

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

	AE-ILD (−) (n = 41)	AE-ILD (+) (n = 7)	p value
Age (years)	69.0 (66.0–75.0)	65.0 (63.0–66.5)	0.019
Sex (male, %)	34 (82.9)	6 (85.7)	1.00
Smoking status			0.57
Current or former	35 (85.4)	7 (100)
Never	6 (14.6)	0 (0)
Previous steroid therapy	4 (9.8)	2 (28.6)	0.21
ECOG PS			0.59
0–1	33 (80.5)	7 (100)
≥2	8 (19.5)	0 (0)
Stage			1.00
III	8 (19.5)	1 (14.3)
IV	33 (80.5)	6 (85.7)
Classification of ILD			1.00
IIPs	38 (92.7)	7 (100)
Non-IIPs	3 (7.3)	0 (0)
ILD pattern			0.42
UIP pattern	22 (53.7)	2 (28.6)
Non-UIP pattern	19 (46.3)	5 (71.4)
SpO₂ at rest (%)	96.0 (95.0–9.07)	96.0 (95.0–97.0)	0.82
FVC (% predicted)	89.0 (78.5–100)	82.0 (81.0–101.0)	0.74
LDH (U/L)	219.0 (194.0–253.0)	224.0 (202.5–257.5)	0.74
KL-6 (U/ml)	789.0 (530.2–1196.0)	893.0 (537.0–1048.0)	0.86
CRP (mg/dl)	0.9 (0.3–1.5)	0.9 (0.8–2.8)	0.58
First-line regimens			0.86
CDDP + PEM	10 (24.4)	1 (14.3)
CBDC + PEM	21 (51.2)	4 (57.1)
PEM	3 (7.3)	1 (14.3)
CBDCA + PTX	7 (17.1)	1 (14.3)
Bev-containing regimens	17 (41.5)	0 (0)	0.041
PEM-containing regimens	34 (82.9)	6 (85.7)	1.00

Data are expressed as group median (interquartile range) or number of patients (%). The p values refer to comparisons between patients with and without AE-ILD. ECOG PS Eastern Cooperative Oncology Group performance status, ILD interstitial lung disease, IIPs idiopathic interstitial pneumonias, UIP usual interstitial pneumonia, FVC forced vital capacity, SpO₂ percutaneous oxygen saturation, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, CRP C-reactive protein, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel

Back to article page